Products : Reagents

Reagent kits containing fluorophor-labeled detectors and buffers (currently under development) will allow ALEX-based detection and quantification of clinically useful biomarker panels for disease diagnosis and prognosis (e.g. early cancer detection, acute myocardial infarction, osteoarthritis, traumatic brain injury, neurodegenerative diseases such as Alzheimers, Parkinsons, and other motosensory neuropathies, diabetes, asthma, infectious diseases, as well as bioterror agents), or assessment of response to drug treatment.

NTI's first test to be introduced into the IVD market will be a highly innovative, next-generation blood-based prostate cancer test. The cancer diagnostics market is on the verge of explosion as scientists approach major breakthroughs in tumor diagnosis and therapy. NTI will implement a panel of protein and microRNA (miRNA) biomarkers for improved diagnosis and population-wide screening, over-coming limitations of the currently existing popular PSA (prostate-specific antigen) test.

With its vast potential for diagnostic analysis in different disease areas, NTI is considering an open-source business model. This will allow companies with biomarker expertise in context with particular diseases to propose reagent kit development utilizing their proprietary biomarkers of choice.